- Previous Close
6.47 - Open
6.39 - Bid 6.39 x 1200
- Ask 6.41 x 1800
- Day's Range
6.36 - 6.49 - 52 Week Range
3.96 - 11.46 - Volume
412,685 - Avg. Volume
2,627,043 - Market Cap (intraday)
2.362B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.13 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 10, 2010
- 1y Target Est
8.67
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
www.bauschhealth.com20,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BHC
View MorePerformance Overview: BHC
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BHC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BHC
View MoreValuation Measures
Market Cap
2.40B
Enterprise Value
22.83B
Trailing P/E
--
Forward P/E
1.43
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.25
Price/Book (mrq)
--
Enterprise Value/Revenue
2.37
Enterprise Value/EBITDA
8.09
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.48%
Return on Assets (ttm)
4.33%
Return on Equity (ttm)
--
Revenue (ttm)
9.62B
Net Income Avi to Common (ttm)
-46M
Diluted EPS (ttm)
-0.13
Balance Sheet and Cash Flow
Total Cash (mrq)
1.18B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
1.8B